
Patients with advanced prostate cancer have a greater chance of survival if treated with a targeted cancer drug in addition to chemotherapy, according to a new study.
Analysis of the study funded by Cancer Research UK and AstraZeneca UK found that adding the drug capivasertib to chemotherapy can improve survival rates for men whose cancer had spread to other parts of the body.